North of Tyne and Gateshead Area Prescribing Committee Agenda

North of Tyne and Gateshead
Area Prescribing Committee
(www.northoftyneapc.nhs.uk)
Tuesday 12th April 2015.
Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt Business Park. 12:30pm

AGENDA

1.  / Apologies for absence
2.  / Declarations of interest
3. / Appeals against previous decisions
·  None
4. / Decision summary from 12/1/16.
Minutes from the meeting 12/1/16 / Enc.1.
Enc.2.
5. / Matters arising not on the agenda
6. / APC Action log
·  Jan 2016 / Enc.3.
7. / Report from the Formulary sub-group
·  Formulary version 6.2 Traffic light list 01.16
·  Draft minutes from meeting held on 3/3/16
·  Decision summary from meeting held on 3/3/16 / On website
Enc.4.
Enc.5.
8. / Report from the Medicines Guidelines and Use Group
·  Minutes from meeting on 2/3/16
·  Guideline(s) for approval
Ø  APC Guideline on Medicines that are Not Suitable for Generic Prescribing
Ø  Primary care prescribing guidelines for specialist infant formulae
Ø  Third Party Ordering
Ø  Atomoxetine Shared Care Guideline for the treatment of ADHD in children and young people
Ø  Dexamfetamine Shared Care Guideline for the treatment of ADHD in children and young people
Ø  Dexamfetamine Shared Care Guideline for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.
Ø  Methylphenidate Shared Care Guideline for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and young people and for Giggle Incontinence in children aged 8 to 16 years
Ø  Methylphenidate Shared Care Guideline for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults
Ø  Naltrexone Shared Care Guidance for use in the management of agitation and/or self-injurious behaviour in patients with autism or learning disabilities. / Enc.6.
Enc.7.
Enc.8.
Enc.9.
Enc.10.
Enc.11.
Enc.12.
Enc.13.
Enc.14.
Enc.15.
9. / Terms Of Reference of new committee / Enc.16.
10. / Establishing Regional Medicines Optimisation Committees – letter from Keith Ridge / Enc.17.
11. / NICE Technology Appraisals published January, February and March
·  TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
·  TA376 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
·  TA377 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
·  TA378 Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy – Negative Appraisal
·  TA379 Nintedanib for treating idiopathic pulmonary fibrosis
·  TA380 Panobinostat for treating multiple myeloma after at least 2 previous treatments
·  TA381 Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
·  TA382 Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)
·  TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
·  TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma
·  TA385 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
·  TA386 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
·  TA23 Updated Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) / Available at:
Guidance by month | NICE
12. / Northern (NHS) Treatment Advisory Group (NTAG).
The following recommendations were finalised by NTAG at their meeting on the and are now available on the website :
·  No update
13. / NHS England Specialised Services
·  SSC1602 Circular Provider Letter regarding ‘NICE Technology Appraisal 370: Bortezomib for previously untreated mantle cell lymphoma’
·  SSC1606 regarding ‘NICE Technology Appraisal 380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
·  SSC1607 regarding ‘Cancer Drugs Fund and NICE Technology Appraisal 376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
·  SSC1608 ‘NICE Technology Appraisal 381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum based chemotherapy’
·  SSC1609 ‘NICE Technology Appraisal 377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated’
·  SSC1610 regarding ‘NICE Technology Appraisal 379: Nintedanib for treating idiopathic pulmonary fibrosis’
·  SSC1611 - Early Access to Medicines Scheme - Treatment as monotherapy of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adult patients whose tumours express programmed death ligand-1 (PD-L1)
·  SSC1612 - Early Access to Medicines Scheme - Treatment as monotherapy of adult patients with advanced renal cell carcinoma after prior therapy
·  SSC1613 - A06/p/a Commissioning Policy: Dialysis Away from Base (DAFB) and Service Specification for DAFB
·  SSC1614 - HIV treatments update: February 2016
·  SSC1614 - HIV treatments update: February 2016 – Appendix 1
·  SSC1614 - HIV treatments update: February 2016 – appendix 2
·  SSC1616 - Individual Funding Requests
·  SSC1617 - NICE Technology Appraisal 384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
·  SSC1618_Early Access to Medicines Scheme Pembrolizumab - Provider letter / Enc.18.
Enc.19.
Enc.20.
Enc.21.
Enc.22.
Enc.23.
Enc.24.
Enc.25.
Enc.26.
Enc.27.
Enc.28.
Enc.29.
Enc.30.
Enc.31.
Enc.32.
14. / Chairman’s action
Updated oral anticoagulant comparison document
Updated Gluten free guidance for North Tyneside and Northumberland / On website
On website
15. / Any other business
16. / Date and time of next meeting:
Tuesday 12th July, 12.30pm.
Room 4, Northumbria House, Unit 7/8 Silver Fox Way,
Cobalt Business Park,
North Tyneside.

Page 3 of 3